PEARRL
  • PEARRL Project
    • Beneficiaries
    • Partner Organisation
    • People >
      • Supervisors >
        • Prof. B. Griffin
        • Prof. M. Kuentz
        • Dr. C. Saal
        • Dr. L. Kalantzi
        • Dr. E. Kostewicz
        • Prof. C. Reppas
        • Prof. J. Dressman
        • Dr. N. Fotaki
        • Dr. R. Holm
        • Dr. M. Vertzoni
        • Dr. K. Box
        • Prof. C. O'Driscoll
      • Researchers >
        • Niklas Köhl (ESR1)
        • Felix Ditzinger (ESR 2)
        • Daniel Price (ESR 3)
        • Georgia Tsakiridou (ESR 4)
        • Sandra Jankovic (ESR 5)
        • Chara Litou (ESR 6)
        • Christina Pentafragka (ESR 7)
        • Rafael Leal Monteiro Paraiso (ESR 8)
        • Laura Henze (ESR 9)
        • Patrick O'Dwyer (ESR 10)
        • Marina Statelova (ESR 11)
        • Mariana Guimarães (ESR 12)
        • Ioannis Loisios-Konstantinidis (ESR 13)
        • Alexandra-Roxana Ilie (ESR 14)
        • Angela Effinger (ESR 15)
      • Scientific Advisory Board >
        • Prof. Carla Caramella
        • Dr. Paul Dickinson
        • Dr. Andrea Edginton
        • Dr. Susanne Keitel
        • Dr. Mehul Mehta
    • PEARRL Wiki >
      • FAQ
      • Glossary
  • Research
    • Workplan
    • WP1: Bio-enabling formulations
    • WP2: Biopharmaceutical tools
    • WP3: In silico methods
    • Results >
      • Scientific Publications
      • Conference Contributions
      • InfoPEARRLs
      • Media
  • Training
    • Local
    • Network-wide
    • PEARRL Online Learning Portal
    • Member Area
  • News
  • Events & Meetings
    • Webinar: Regulatory Science Apprentice
    • Annual Meeting 2019
    • Model Informed Drug Development Symposium 2019
    • Annual Meeting 2018
    • Regulatory Science Symposium 2018
    • Annual Meeting 2017
    • Regulatory Science Symposium 2017
    • PEARRL Calendar
    • International Conferences
  • PEARRL Project
    • Beneficiaries
    • Partner Organisation
    • People >
      • Supervisors >
        • Prof. B. Griffin
        • Prof. M. Kuentz
        • Dr. C. Saal
        • Dr. L. Kalantzi
        • Dr. E. Kostewicz
        • Prof. C. Reppas
        • Prof. J. Dressman
        • Dr. N. Fotaki
        • Dr. R. Holm
        • Dr. M. Vertzoni
        • Dr. K. Box
        • Prof. C. O'Driscoll
      • Researchers >
        • Niklas Köhl (ESR1)
        • Felix Ditzinger (ESR 2)
        • Daniel Price (ESR 3)
        • Georgia Tsakiridou (ESR 4)
        • Sandra Jankovic (ESR 5)
        • Chara Litou (ESR 6)
        • Christina Pentafragka (ESR 7)
        • Rafael Leal Monteiro Paraiso (ESR 8)
        • Laura Henze (ESR 9)
        • Patrick O'Dwyer (ESR 10)
        • Marina Statelova (ESR 11)
        • Mariana Guimarães (ESR 12)
        • Ioannis Loisios-Konstantinidis (ESR 13)
        • Alexandra-Roxana Ilie (ESR 14)
        • Angela Effinger (ESR 15)
      • Scientific Advisory Board >
        • Prof. Carla Caramella
        • Dr. Paul Dickinson
        • Dr. Andrea Edginton
        • Dr. Susanne Keitel
        • Dr. Mehul Mehta
    • PEARRL Wiki >
      • FAQ
      • Glossary
  • Research
    • Workplan
    • WP1: Bio-enabling formulations
    • WP2: Biopharmaceutical tools
    • WP3: In silico methods
    • Results >
      • Scientific Publications
      • Conference Contributions
      • InfoPEARRLs
      • Media
  • Training
    • Local
    • Network-wide
    • PEARRL Online Learning Portal
    • Member Area
  • News
  • Events & Meetings
    • Webinar: Regulatory Science Apprentice
    • Annual Meeting 2019
    • Model Informed Drug Development Symposium 2019
    • Annual Meeting 2018
    • Regulatory Science Symposium 2018
    • Annual Meeting 2017
    • Regulatory Science Symposium 2017
    • PEARRL Calendar
    • International Conferences

Niklas Köhl (ESR1) successfully defends his PhD

6/3/2020

0 Comments

 
We are happy to congratulate Niklas Köhl (ESR1) on successfully defending his PhD. We have also interviewed Niklas about his research project, his time within PEARRL and plans for the future.
Picture
1. What has your research project focused on and what are your key results and innovations coming from your research project?
My research focused on the development of lipid-based formulations for new emerging drug types to improve oral bioavailability. We focused on poorly lipid and aqueous soluble drugs and the development of different lipid based formulation types for these compounds. Such an approach allows to explore the benefits and risks associated with the different lipid-based formulations in order to guide the formulation development of low lipid soluble compounds within the field of lipid-based formulations.
As a result of this project, we developed various lipid-based formulations, which are applicable from very early phases of the drug product development process to formulations that can be marketed. Furthermore, we demonstrated that lipid-based formulations have the ability to improve oral bioavailability for low lipid soluble drugs.  
 
2. What impact does your research project and your outcomes have?
Lipid-based formulations is a rarely used formulation approach due to a low solubility in lipid excipients of many new drugs. Our research informed the scientific community that lipid-based formulations are a viable approach for drugs that show a limited lipid solubility. Therefore, potentially more drugs can be formulated as a lipid-based formulation to improve oral bioavailability from very early phases to late phases as well as the commercial stage of drug product development. The wider application of lipid-based formulations potentially increases patient compliance and results in improved drug products on the market.
 
3. What were your personal highlights over the course of your research project?
A key highlight was being part of such a European wide network that combines academia, industry and regulatory authorities. Throughout my research project, it was great to get insights into all three areas in the context of pharmaceutical development. Moreover, I enjoyed collaborating with fellow scientists and project partners, which fostered great science and allowed me to acquire a unique set of skills and encouraged my personal development. Especially, events such as the PEARRL weeks of wisdom stimulated such collaborations within, but also with scientists outside of PEARRL.
 
4. Are there any elements of the training you received that you find should be integrated in local doctoral programmes?
Besides transferable skills training such as scientific writing and presentation training, I think within the pharmaceutical doctoral programmes training on regulatory topics/requirements are beneficial.
 
5. How did the PEARRL network impact your doctoral experience?
The training within PEARRL gave me the opportunity to look beyond my own research topic and allowed me to broaden my knowledge in different research areas and acquire an unique set of skills. In addition, I had great support, resources and manifold possibilities to collaborate which lead to great scientific results. Also, the relocation to Ireland was great to learn about a different culture and meet new people.
 
6. What are your plans for the future?
After PEARRL, I am going to start at Janssen Pharmaceutica in the area of formulation development, which matches the work I have been doing during my PhD.

0 Comments

Your comment will be posted after it is approved.


Leave a Reply.

    Archives

    September 2020
    June 2020
    May 2020
    March 2020
    December 2019
    July 2019
    June 2019
    May 2019
    March 2019
    February 2019
    January 2019
    December 2018
    September 2018
    June 2018
    May 2018
    April 2018
    March 2018
    February 2018
    December 2017
    November 2017
    October 2017
    September 2017
    July 2017
    June 2017
    April 2017
    January 2017
    November 2016
    October 2016
    September 2016
    July 2016
    May 2016
    March 2016
    February 2016

    Categories

    All
    Events
    Milestone
    People
    Research

    RSS Feed

Picture
This project has received funding from the European Union’s Horizon 2020 Research and Innovation Programme under grant agreement No 674909.
Disclaimer | Member Area
© accelopment Schweiz AG 2019. ALL RIGHTS RESERVED.